Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

This study is testing whether mesalamine (an anti-inflammatory drug commonly used for inflammatory bowel disease) can prevent colorectal cancer in people with Lynch syndrome — an inherited condition that significantly raises the risk of developing colon cancer. **You may be eligible if:** - You carry a confirmed genetic mutation in MLH1, MSH2, or MSH6 that causes Lynch syndrome - You are 30 or older and currently cancer-free (or have had polyps removed) - You are using effective contraception or are post-menopausal (if female) **You may NOT be eligible if:** - You carry a PMS2 gene mutation (a different Lynch syndrome variant) - You have had stage 3 or 4 colorectal cancer - You regularly take aspirin, NSAIDs, or COX-2 inhibitors - You have had a colectomy (surgical removal of the colon) - You are allergic to 5-ASA (mesalamine) - Your kidney or liver function is severely impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.